Phase III HUMAN study shows that new pill for patients with advanced pancreatic cancer live significantly longer than standard chemotherapy
Read Full Article
#PancreaticCancer #PhaseIII #TargetedTherapy
Read Full Article
#PancreaticCancer #PhaseIII #TargetedTherapy
The New England Journal of Medicine
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer | NEJM
Current therapies offer limited benefit for patients with previously treated metastatic
pancreatic ductal adenocarcinoma (mPDAC). Aberrant activation of the RAS pathway is
the key driver of PDAC, w...
pancreatic ductal adenocarcinoma (mPDAC). Aberrant activation of the RAS pathway is
the key driver of PDAC, w...